Skip to main content

Table 2 Adverse events of the subjects

From: Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial

  SQT (n = 195) PBAT (n = 195) p-value
n (%) n (%)
Bloating 21 (22.6) 11 (15.3) 0.097
Epigastric soreness 15 (16.1) 17 (23.6) 0.854
Anorexia 2 (2.2) 1 (1.4) 1.000
Taste distortions 24 (25.8) 4 (5.6) <0.001
Nausea 14 (15.1) 6 (8.3) 0.108
Vomiting 0 2 (2.8) 0.478
Abdominal pain 4 (4.3) 4 (5.6) 0.721
Headache 1 (1.1) 2 (2.8) 1.000
Dyspepsia 4 (4.3) 4 (5.6) 0.721
Diarrhea 2 (2.2) 12 (16.7) 0.014
Constipation 2 (2.2) 3 (4.2) 1.000
Reflux 1 (1.1) 1 (1.4) 0.478
Rash and itching 2 (2.2) 5 (2.8) 0.446
Dizziness 1 (1.1) 0 1.000
Stool color change 0 3 (4.2) 0.246
Total 93 (47.7) 72 (36.9) 0.040
  1. Bold style, means statistical significance
  2. SQT sequential therapy, PBAT quadruple therapy consist of pantoprazole, bismuth, amoxicillin, and tetracycline